SIRPA and myelodysplastic syndrome: In line with the previous study in AML/MDS cohort (5), the results of the study suggested that SIRPα variant mismatch in allo-HSCT could elicit non-self recognition and innate immune activation, which further promotes adaptive immunity and subsequently leads to a reduced risk of relapse and a higher risk of cGVHD.